TABLE 1.

Characteristics of patients in this study.

		NLR			PLR			MLR
Characteristic	Total (N = 111) N (%)	<5.0 (n = 94, 84.7%)	≥5.0 (n = 17, 15.3%)	P value	<135 (n = 55, 49.5%)	≥135 (n = 56, 50.5%)	P value	<0.31 (n = 61, 55.0%)	>0.31 (n = 50, 45.0%)	P value
Sex
Female	55 (49.5%)	47	8	0.823	31	28	0.502	28	27	0.396
Male	56 (50.5%)	47	9		24	28		33	23
Age
≥ 65	23 (20.7%)	20	3	0.767	12	11	0.777	12	11	0.763
< 65	88 (79.2%)	74	14		43	45		49	39
Cancer type
Gastric cancer	50 (42.6%)	45	5	0.159	21	29	0.150	28	22	0.841
Colorectal cancer	61 (57.6%)	49	12		34	27		33	28
Treatment line
First line	51 (45.9%)	46	5	0.137	29	22	0.155	34	17	0.035
> First line	60 (54.1%)	48	12		26	34		27	33
Liver metastasis
No	55 (49.5%)	49	6	0.210	27	28	0.924	34	21	0.150
Yes	56 (50.5%)	45	11		28	28		27	29
Lung metastasis
No	84 (75.6%)	70	14	0.486	43	41	0.542	48	36	0.414
Yes	27 (24.4%)	24	3		12	15		13	14
Peritoneal metastasis
No	90 (81.1%)	76	14	0.884	48	42	0.099	51	39	0.453
Yes	21 (18.9%)	18	3		7	14		10	11
With chemotherapy
No	37 (33.3%)	30	7	0.456	19	18	0.788	17	20	0.177
Yes	74 (66.7%)	64	10		36	38		44	30
With Targeted therapy
No	67 (60.4%)	60	7	0.079	36	31	0.277	41	26	0.103
Yes	44 (39.6%)	34	10		19	25		20	24
With Radiotherapy
No	104 (93.7%)	89	15	0.314	51	53	0.678	58	46	0.506
Yes	7 (6.3%)	5	2		4	3		3	4

P values in bold indicate statistically significant differences (P < 0.05).

MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.